Search Results - Christoph Ehlken

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

    A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. by Christine Schmucker, Christoph Ehlken, Hansjuergen T Agostini, Gerd Antes, Gerta Ruecker, Monika Lelgemann, Yoon K Loke

    Published 2012-01-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.

    Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. by Christine M Schmucker, Gerta Rücker, Harriet Sommer, Gianni Virgili, Yoon K Loke, Patrick Oeller, Hansjuergen Agostini, Christoph Ehlken

    Published 2015-01-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: